Skip to content

Study · Not a test of the peptide alone · 2024

2 results

INTERACTIONS OF METFORMIN AND OTHER MEDICATIONS IN REDUCING THE ODDS OF AGE-RELATED MACULAR DEGENERATION IN A COHORT OF PATIENTS WITH DIABETES.

Shaw L, Khanna S, Hyman MJ, Ham S, Blitzer A, Parvar SP, Soo J, Flores A, Hariprasad S, Skondra D

Retina (Philadelphia, Pa.)1 Feb 2024Cited by 8 (Europe PMC)

PMID37782954 (opens in a new tab)DOI10.1097/iae.0000000000003949 (opens in a new tab)PepBankPUB-37782954
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther

    In diabetic patients, grouped exenatide, sitagliptin and pramlintide use alone was linked to slightly increased odds of age-related macular degeneration.

    In plain wordsIn diabetic patients, grouped exenatide, sitagliptin and pramlintide use alone was linked to slightly higher odds of age-related macular degeneration.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseOdds of age-related macular degeneration with grouped medications
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye

    Source sentences

    Summary
    The other medication group (exenatide, sitagliptin, and pramlintide) slightly increased the odds of developing AMD when taken alone, but the combination with metformin alleviated this effect.
    2 context sentences
    Summary · context
    This is a case-control analysis using data from the Merative MarketScan Commercial and Medicare databases.
    Summary · context
    Patients were 55 years and older with newly diagnosed AMD and matched to controls.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther

    In diabetic patients, metformin combined with grouped exenatide, sitagliptin and pramlintide use was associated with attenuation of their increased macular degeneration odds.

    In plain wordsIn diabetic patients, metformin with grouped exenatide, sitagliptin and pramlintide use was linked to lower macular degeneration odds than grouped use alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseMetformin interaction with grouped medications
    Study

    n: not reported in source

    Comparator
    Grouped exenatide, sitagliptin and pramlintide without metformin
    Outcome group
    Vision and retina · Eye

    Source sentences

    Summary
    The other medication group (exenatide, sitagliptin, and pramlintide) slightly increased the odds of developing AMD when taken alone, but the combination with metformin alleviated this effect.
    2 context sentences
    Summary · context
    This is a case-control analysis using data from the Merative MarketScan Commercial and Medicare databases.
    Summary · context
    Patients were 55 years and older with newly diagnosed AMD and matched to controls.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.